GLP1R and diabetes mellitus: In addition to non-pharmacological interventions, a randomized trial of adults who were obese without diabetes demonstrated that tirzepatide, a dual agonist for glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), reduced SBP by 7.4 mmHg for 5 mg daily dose and by 10.6 mmHg at a 10 mg daily dose compared to placebo over 72 weeks [28, 29].